Building a CAR-T CMC Strategy on a Limited Budget

Early developers do not need a finalized commercial process before first-in-human studies, but they do need a clear plan for managing cost, scalability, comparability, and future manufacturing changes

By
Kate Fynes
October 6, 2026
8 min

The Medicine Maker

1

Early developers must balance speed and risk in their CMC strategy to achieve first in human (FIH) milestones while managing limited resources.
2

A focus on speed in CMC strategy can lead to challenges later, including increased costs and regulatory scrutiny if processes need to change post-FIH.
3

A staged CMC development pathway helps connect current processes with future goals, identifying gaps and necessary changes for regulatory compliance.
4

Cost-of-goods modeling is crucial for early CAR-T programs to identify potential long-term viability issues and prioritize development spending.
5

Sensitivity analysis aids developers in determining which process improvements to pursue based on their impact on cost, feasibility, and scalability.

Building a CAR-T CMC Strategy on a Limited Budget

1

2

3

4

5

Original Source(s)

Building a CAR-T CMC Strategy on a Limited Budget

Related Content

MEK inhibition achieves robust and durable responses in Erdheim–Chester disease

Reading Skin Cancer’s Molecular Fingerprint

Correction to “Combined inhibition of de novo pyrimidine synthesis and ATR promotes ATF4-mediated cell death in TP53-deficient ALL”